Journal of psychosomatic research · 2013
Exposure to secondhand smoke and depression and anxiety: a report from two studies in the Netherlands.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bot Mariska, Vink Jacqueline M, Willemsen Gonneke, Smit Johannes H, Neuteboom Jacoline, Kluft Cornelis, Boomsma Dorret I, Penninx Brenda W J H
Аннотация
OBJECTIVE: Previous population-based studies suggest that exposure to secondhand smoke (SHS) is related to increased depressive symptoms and poor mental health among non-smokers. We examined whether these associations could be replicated in two independent Dutch samples.
METHODS: Non-smoking adults were selected from two studies: 1) the Netherlands Study of Depression and Anxiety (NESDA), comprising individuals with current and remitted depressive and/or anxiety disorders, and healthy controls and 2) the Netherlands Twin Register (NTR), comprising twin-family studies on health-related behaviors. In both studies, SHS exposure was assessed with plasma cotinine levels (1-14ng/ml vs. <1ng/ml). In NESDA, outcomes were current depressive and/or anxiety disorders, and depression and anxiety symptom severity scores. In NTR, the Adult Self Report derived DSM-subscales for depressive and anxiety problems, and anxious depressive scores were analyzed.
RESULTS: In NESDA non-smokers (n=1757), increased plasma cotinine level (≥1ng/ml) was not related to current depressive and/or anxiety disorders [odds ratio (OR) 0.96, P=.77], nor to depression or anxiety severity indicators. Similarly, in NTR non-smokers (n=1088) cotinine levels ≥1ng/ml were not associated with the DSM-subscale for depressive problems [unstandardized regression coefficient (B) 0.04, P=.88], nor to other depression and anxiety measures.
CONCLUSIONS: In non-smoking adults from patient and population samples, we found no evidence that plasma cotinine levels were related to either depressive and/or anxiety disorders, or to depressive and anxiety symptoms. This suggests that SHS exposure is not related to depression and anxiety in non-smoking adults.
METHODS: Non-smoking adults were selected from two studies: 1) the Netherlands Study of Depression and Anxiety (NESDA), comprising individuals with current and remitted depressive and/or anxiety disorders, and healthy controls and 2) the Netherlands Twin Register (NTR), comprising twin-family studies on health-related behaviors. In both studies, SHS exposure was assessed with plasma cotinine levels (1-14ng/ml vs. <1ng/ml). In NESDA, outcomes were current depressive and/or anxiety disorders, and depression and anxiety symptom severity scores. In NTR, the Adult Self Report derived DSM-subscales for depressive and anxiety problems, and anxious depressive scores were analyzed.
RESULTS: In NESDA non-smokers (n=1757), increased plasma cotinine level (≥1ng/ml) was not related to current depressive and/or anxiety disorders [odds ratio (OR) 0.96, P=.77], nor to depression or anxiety severity indicators. Similarly, in NTR non-smokers (n=1088) cotinine levels ≥1ng/ml were not associated with the DSM-subscale for depressive problems [unstandardized regression coefficient (B) 0.04, P=.88], nor to other depression and anxiety measures.
CONCLUSIONS: In non-smoking adults from patient and population samples, we found no evidence that plasma cotinine levels were related to either depressive and/or anxiety disorders, or to depressive and anxiety symptoms. This suggests that SHS exposure is not related to depression and anxiety in non-smoking adults.